Naschberger, E., Croner, R.S., Merkel, S., Dimmler, A., Tripal, P., Amann, K.U., Kremmer, E., Brueckl, W.M., Papadopoulos, T., Hohenadl, C., Hohenberger, W. and Struzl, M. (2008) Angiostatic Immune Reaction in Colorectal Carcinomas: Impact on Survival and Perspectives for Antiangiogenic Therapy. International Journal of Cancer, 123, 2120-2129.
https://doi.org/10.1002/ijc.23764

has been cited by the following article:

• TITLE: hGBP-1 Expression Predicts Shorter Progression-Free Survival in Ovarian Cancers, While Contributing to Paclitaxel Resistance

  AUTHORS: Suzan Wadi, Aaron R. Tipton, Jill A. Trendel, Sadik A. Khuder, Deborah J. Vestal

  KEYWORDS: Guanylate-Binding Protein, Paclitaxel, Ovarian Cancer, Drug Resistance, GTPase, TUBB3

  JOURNAL NAME: Journal of Cancer Therapy, Vol.7 No.13, December 8, 2016

  ABSTRACT: Ovarian cancer is the gynecological cancer with the poorest prognosis. One significant reason is the development of resistance to the chemotherapeutic drugs used in its treatment. The large GTPase, hGBP-1, has been implicated in paclitaxel resistance in ovarian cell lines. Forced expression of hGBP-1 in SKOV3 ovarian cancer cells protects them from paclitaxel-induced cell death. However, prior to this study, nothing was known about whether hGBP-1 was expressed in ovarian tumors and whether its expression correlated with paclitaxel resistance. hGBP-1 is expressed in 17% of ovarian tumors from patients that have not yet received treatment. However, at least 80% of the ovarian tumors that recurred after therapies that included a taxane, either paclitaxel or docetaxel, were positive for hGBP-1. In addition, hGBP-1 expression predicts a significantly shorter progression-free survival in ovarian cancers. Based on these studies, hGBP-1 could prove to be a potential biomarker for paclitaxel resistance in ovarian cancer.